Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 211.19 USD -1.24%
Market Cap: 372.8B USD
Have any thoughts about
Abbvie Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one ABBV stock under the Base Case scenario is 143.01 USD. Compared to the current market price of 211.19 USD, Abbvie Inc is Overvalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABBV Relative Value
Base Case
143.01 USD
Overvaluation 32%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.6
P/S
P/S
Price to Sales
6.6
vs History
0
vs Industry
60
Median 3Y
4.6
Median 5Y
4.2
Industry
7.3
Forward
6.1
More Details
87.9
P/E
P/E
Price to Earnings
87.9
vs History
0
vs Industry
3
Median 3Y
34.9
Median 5Y
26.7
Industry
21.6
Forward
16.8
More Details
19.9
P/OCF
P/OCF
Price to OCF
19.9
vs History
3
vs Industry
11
Median 3Y
10.8
Median 5Y
9.8
Industry
19.8
More Details
17.1
P/FCFE
P/FCFE
Price to FCFE
17.1
vs History
31
vs Industry
10
Median 3Y
17.2
Median 5Y
14.8
Industry
24.9
More Details
112.1
P/B
P/B
Price to Book Value
112.1
vs History
0
vs Industry
1
Median 3Y
19.8
Median 5Y
15.3
Industry
2.4
More Details
7.6
EV/S
EV/S
Enterprise Value to Sales
7.6
vs History
0
vs Industry
49
Median 3Y
5.4
Median 5Y
5.2
Industry
7.4
Forward
7
More Details
10.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.9
vs History
1
vs Industry
39
Median 3Y
7.6
Median 5Y
7.5
Industry
9.3
More Details
17.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.2
vs History
0
vs Industry
8
Median 3Y
11.1
Median 5Y
11
Industry
3.9
Forward
14.5
More Details
25.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
25.9
vs History
1
vs Industry
6
Median 3Y
15.7
Median 5Y
15.7
Industry
3.7
Forward
15
More Details
22.8
EV/OCF
EV/OCF
Enterprise Value to OCF
22.8
vs History
3
vs Industry
10
Median 3Y
13
Median 5Y
12.7
Industry
4.9
More Details
24.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
24.1
vs History
3
vs Industry
8
Median 3Y
13.4
Median 5Y
13.2
Industry
3.2
More Details
4.4
EV/IC
EV/IC
Enterprise Value to IC
4.4
vs History
0
vs Industry
37
Median 3Y
3.1
Median 5Y
2.8
Industry
4.3
More Details

Multiples Across Competitors

ABBV Competitors Multiples
Abbvie Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Abbvie Inc
NYSE:ABBV
372.5B USD 6.6 87.9 17.2 25.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 277 900.2 -172 423.5 -209 377 -206 987.8
US
Amgen Inc
NASDAQ:AMGN
168.5B USD 5 41.2 16.6 29.4
US
Gilead Sciences Inc
NASDAQ:GILD
133.4B USD 4.6 277.8 10.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.3B USD 11.8 -243.8 26.7 27.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 941.9 -495.5 -539.6 -525.2
AU
CSL Ltd
ASX:CSL
121.2B AUD 5.1 28.1 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.5B USD 5.1 16.4 10.8 12
US
Seagen Inc
F:SGT
39.3B EUR 18.7 -57.4 -61.7 -55.7
NL
argenx SE
XBRU:ARGX
33.8B EUR 16.9 44.4 328.2 -2 418.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
32.8B USD 14.4 -116.3 -248.9 -169.1
P/S Multiple
Revenue Growth P/S to Growth
US
Abbvie Inc
NYSE:ABBV
Average P/S: 3 298 175.5
6.6
8%
0.8
FR
Pharnext SCA
OTC:PNEXF
36 277 900.2
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.8
10%
1.2
US
E
Epizyme Inc
F:EPE
1 941.9
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.7
30%
0.6
NL
argenx SE
XBRU:ARGX
16.9
37%
0.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.4
28%
0.5
P/E Multiple
Earnings Growth PEG
US
Abbvie Inc
NYSE:ABBV
Average P/E: 82.6
87.9
88%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -172 423.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
41.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
277.8
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -243.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -495.5 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.4 N/A N/A
NL
argenx SE
XBRU:ARGX
44.4
19%
2.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -116.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Abbvie Inc
NYSE:ABBV
Average EV/EBITDA: 61.1
17.2
13%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 377 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -539.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.8
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
NL
argenx SE
XBRU:ARGX
328.2
168%
2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -248.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Abbvie Inc
NYSE:ABBV
Average EV/EBIT: 21.8
25.9
29%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -206 987.8 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
29.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.9
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 418.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -169.1 N/A N/A

See Also

Summary
ABBV intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBV stock valuation using valuation multiples.
Wall Street Estimates
ABBV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 239,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.